{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:42:44Z","timestamp":1790628164055,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1136\/ard-2024-226024","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:35:53Z","timestamp":1722393353000},"page":"1657-1665","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial"],"prefix":"10.1016","volume":"83","clinical-trial-number":[{"clinical-trial-number":"nct01491815","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5037-5546","authenticated-orcid":false,"given":"Kristina","family":"Lend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Lampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2950-5670","authenticated-orcid":false,"given":"Leonid","family":"Padyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-6818","authenticated-orcid":false,"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte Schrumpf","family":"Heiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan C","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6274-1934","authenticated-orcid":false,"given":"Michael T","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-467X","authenticated-orcid":false,"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"H\u00f8rslev-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6881-9552","authenticated-orcid":false,"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6972-5603","authenticated-orcid":false,"given":"Tuulikki","family":"Sokka-Isler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdur","family":"Grondal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3510-5632","authenticated-orcid":false,"given":"Giulia","family":"Frazzei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Christiaans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1924-7460","authenticated-orcid":false,"given":"Gertjan","family":"Wolbink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9600-1312","authenticated-orcid":false,"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos W R","family":"Twisk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2024-226024_bib1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(09)60008-8","article-title":"Rheumatoid arthritis","volume":"373","author":"Klareskog","year":"2009","journal-title":"Lancet"},{"key":"10.1136\/ard-2024-226024_bib2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/art.21575","article-title":"A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination","volume":"54","author":"Klareskog","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226024_bib3","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1136\/ard.2005.041079","article-title":"Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles","volume":"65","author":"Linn-Rasker","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib4","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1002\/art.20553","article-title":"A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis","volume":"50","author":"Padyukov","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226024_bib5","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1136\/annrheumdis-2015-207942","article-title":"Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial","volume":"75","author":"Sokolove","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib6","doi-asserted-by":"crossref","first-page":"e000345","DOI":"10.1136\/rmdopen-2016-000345","article-title":"Baseline autoantibodies preferentially impact abatacept efficacy in patients with rheumatoid arthritis who are biologic na\u00efve: 6-month results from a real-world, international, prospective study","volume":"3","author":"Alten","year":"2017","journal-title":"RMD Open"},{"key":"10.1136\/ard-2024-226024_bib7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/rheumatology\/keaa393","article-title":"The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries","volume":"60","author":"Courvoisier","year":"2021","journal-title":"Rheumatol (Sunnyvale)"},{"key":"10.1136\/ard-2024-226024_bib8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s40744-023-00552-2","article-title":"Benefits of autoantibody enrichment in early rheumatoidarthritis: analysis of efficacy outcomes in four pooled abatacept trials","volume":"10","author":"Michaud","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1136\/ard-2024-226024_bib9","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3899\/jrheum.170007","article-title":"Effect of anticitrullinated protein antibody status on response to abatacept or antitumor necrosis factor-\u03b1 therapy in patients with rheumatoid arthritis: a US national observational study","volume":"45","author":"Harrold","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1136\/ard-2024-226024_bib10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s13075-021-02607-7","article-title":"HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA","volume":"23","author":"Rigby","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226024_bib11","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1038\/s41598-024-56987-2","article-title":"Association of HLA-DRB1 locus with treatment response to abatacept or TNF inhibitors in patients with seropositive rheumatoid arthritis","volume":"14","author":"Cha","year":"2024","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2024-226024_bib12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.2015.3435","article-title":"Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response","volume":"313","author":"Viatte","year":"2015","journal-title":"JAMA"},{"key":"10.1136\/ard-2024-226024_bib13","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"10.1136\/ard-2024-226024_bib14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13063-017-1891-x","volume":"18","author":"Glinatsi","year":"2017","journal-title":"Trials"},{"key":"10.1136\/ard-2024-226024_bib16","doi-asserted-by":"crossref","first-page":"e64683","DOI":"10.1371\/journal.pone.0064683","article-title":"Imputing amino acid polymorphisms in human leukocyte antigens","volume":"8","author":"Jia","year":"2013","journal-title":"PLoS One"},{"key":"10.1136\/ard-2024-226024_bib17","first-page":"S100","article-title":"The simplified disease activity index (SDAI) and the clinical disease activity index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-226024_bib18","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1136\/ard.2007.084459","volume":"68","author":"Wells","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib19","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"van Gestel","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226024_bib20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"Rheumatoid arthritis classification criteria: an American College of rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib21","first-page":"455","article-title":"Presence of anti-cyclic citrullinated peptide antibodies is associated with better treatment response to abatacept but not to TNF inhibitors in patients with rheumatoid arthritis: a meta-analysis","volume":"38","author":"Alemao","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/ard-2024-226024_bib22","article-title":"The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials","author":"Takase-Minegishi","year":"2024","journal-title":"Rheumatol (Sunnyvale)"},{"key":"10.1136\/ard-2024-226024_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41423-020-00529-z","article-title":"Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases","volume":"18","author":"Yoshitomi","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1136\/ard-2024-226024_bib24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1093\/rheumatology\/keab454","article-title":"Blood PD-1+TFh and CTLA-4+CD4+ T cells predict remission after CTLA-4Ig treatment in early rheumatoid arthritis","volume":"61","author":"Aldridge","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"10.1136\/ard-2024-226024_bib25","article-title":"Circulating Tfh cells are differentially modified by abatacept or TNF blockers and predict treatment response in rheumatoid arthritis","author":"Monjo-Henry","year":"2024","journal-title":"Rheumatol (Sunnyvale)"},{"key":"10.1136\/ard-2024-226024_bib26","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature20810","article-title":"Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis","volume":"542","author":"Rao","year":"2017","journal-title":"Nat New Biol"},{"key":"10.1136\/ard-2024-226024_bib27","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/rheumatology\/kez169","article-title":"Two populations of circulating PD-1hiCD4 T cells with distinct B cell helping capacity are elevated in early rheumatoid arthritis","volume":"58","author":"Fortea-Gordo","year":"2019","journal-title":"Rheumatol (Oxford)"},{"key":"10.1136\/ard-2024-226024_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13075-018-1520-4","article-title":"Baseline autoantibody profile in rheumatoid arthritisis associated with early treatment response but not long-term outcomes","volume":"20","author":"de Moel","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226024_bib29","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13075-020-02191-2","article-title":"Presence of autoantibodies in \u2018seronegative\u2019 rheumatoid arthritis associates with classical risk factors and high disease activity","volume":"22","author":"Reed","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226024_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1136\/annrheumdis-2023-eular.2284","article-title":"POS0327\u2005Speed of response matters: post-hoc analysis of patients with early seronegative rheumatoid arthritis included in the carera trial","volume":"82","author":"Pazmino","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib31","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1136\/ard.2009.118018","article-title":"HLA-DRB1*0901 lowers anti-cyclic citrullinated peptide antibody levels in Japanese patients with rheumatoid arthritis","volume":"69","author":"Okada","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib32","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/art.34421","article-title":"Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis","volume":"64","author":"Laki","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2024-226024_bib33","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2017-211430","article-title":"Shared epitope positivity is related to efficacy of abatacept in rheumatoid arthritis","volume":"77","author":"Oryoji","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2024-226024_bib34","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s13075-021-02612-w","article-title":"Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis","volume":"23","author":"Hirose","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2024-226024_bib35","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s42358-024-00352-4","article-title":"Comparative effectiveness of abatacept versus TNF inhibitors in rheumatoid arthritis patients who are ACPA and shared epitope positive","volume":"64","author":"Harrold","year":"2024","journal-title":"Adv Rheumatol"},{"key":"10.1136\/ard-2024-226024_bib36","doi-asserted-by":"crossref","first-page":"15250","DOI":"10.1038\/s41598-023-42324-6","article-title":"Carriers of HLA-DRB1*04:05 have a better clinical response to abatacept in rheumatoid arthritis","volume":"13","author":"Inoue","year":"2023","journal-title":"Sci Rep"},{"key":"10.1136\/ard-2024-226024_bib37","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.semarthrit.2013.09.004","article-title":"The performance of matrices in daily clinical practice to predict rapid radiologic progression in patients with early RA","volume":"43","author":"De Cock","year":"2014","journal-title":"Semin Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724665684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2024-226024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T08:52:01Z","timestamp":1739523121000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724665684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0003496724665684"],"URL":"https:\/\/doi.org\/10.1136\/ard-2024-226024","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2024-226024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 \u00a9 Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by Elsevier Inc on behalf of EULAR. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}